As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:
9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -13 -13 |
55%
55%
|
|
| EBIT (Operating Income) EBIT | -13 -13 |
55%
55%
|
|
| Net Profit | -12 -12 |
47%
47%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
| Head office | United Kingdom |
| CEO | Abizer Gaslightwala |
| Employees | 9 |
| Founded | 2004 |
| Website | www.akaritx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


